Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Public ClinicalTrials.gov record NCT01312922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks
Study identification
- NCT ID
- NCT01312922
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- PharmaNeuroBoost N.V.
- Industry
- Enrollment
- 555 participants
Conditions and interventions
Conditions
Interventions
- PNB01 fixed dose combination of pipamperone and citalopram Drug
- Citalopram Drug
- Pipamperone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2011
- Primary completion
- Oct 31, 2012
- Completion
- Nov 30, 2012
- Last update posted
- Apr 6, 2022
2011 – 2012
United States locations
- U.S. sites
- 26
- U.S. states
- 11
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 103 | Glendale | California | — | — |
| Site 101 | National City | California | — | — |
| Site 113 | Riverside | California | — | — |
| Site 106 | San Diego | California | — | — |
| Site 116 | San Diego | California | — | — |
| Site 112 | Fort Myers | Florida | — | — |
| Site 135 | Miami | Florida | — | — |
| Site 108 | Winter Park | Florida | — | — |
| Site 133 | Atlanta | Georgia | — | — |
| Site 128 | Smyrna | Georgia | — | — |
| Site 132 | Libertyville | Illinois | — | — |
| Site 117 | Schaumburg | Illinois | — | — |
| Site 110 | Baltimore | Maryland | — | — |
| Site 109 | Flowood | Mississippi | — | — |
| Site 115 | New York | New York | — | — |
| Site 126 | Beachwood | Ohio | — | — |
| Site 127 | Cincinnati | Ohio | — | — |
| Site 124 | Middleburg Heights | Ohio | — | — |
| Site 105 | Allentown | Pennsylvania | — | — |
| Site 123 | Media | Pennsylvania | — | — |
| Site 122 | Philadelphia | Pennsylvania | — | — |
| Site 119 | Austin | Texas | — | — |
| Site 104 | Dallas | Texas | — | — |
| Site 102 | Wichita Falls | Texas | — | — |
| Site 107 | Kirkland | Washington | — | — |
| Site 134 | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01312922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01312922 live on ClinicalTrials.gov.